ALK and non-small cell lung carcinoma: The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) fusion gene is presented in 3% to 7% of NSCLC, and is an important molecular mutation.[2–4] Crizotinib is a first-generation ALK inhibitor, and was first approved for the treatment of patients with ALK-rearrangement (ALK+).